Background & relevance

In a short window of time, new drugs for HER2+ MBC have become available. This created both clinical opportunity and uncertainty regarding the selection and sequencing of therapy.

Regulatory approval status of targeted therapies for HER2+ MBC (indications limited to HER2+ MBC setting, status 3 October 2023)